Wednesday, 8 August 2012

Levetiracetam 100 mg / ml oral solution





1. Name Of The Medicinal Product



Levetiracetam 100 mg/ml oral solution


2. Qualitative And Quantitative Composition



Each ml contains 100 mg levetiracetam



Each ml contains 2.7 mg of methyl parahydroxybenzoate (E218), 0.3 mg of propyl parahydroxybenzoate (E216) and 300 mg of maltitol liquid.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Oral solution.



Clear and colourless solution.



4. Clinical Particulars



4.1 Therapeutic Indications



Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.



Levetiracetam is indicated as adjunctive therapy



• in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy.



• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.



• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.



4.2 Posology And Method Of Administration



Posology



Monotherapy for adults and adolescents from 16 years of age



The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.



Add-on therapy for adults (



The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.



Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.



Special populations



Elderly (65 years and older)



Adjustment of the dose is recommended in elderly patients with compromised renal function (see "Patients with renal impairment" below).



Renal impairment



The daily dose must be individualised according to renal function.



For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:





Then CLcr is adjusted for body surface area (BSA) as follows:





Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function






















Group




Creatinine clearance



(ml/min/1.73m2)




Dosage and frequency




Normal




> 80




500 to 1,500 mg twice daily




Mild




50-79




500 to 1,000 mg twice daily




Moderate




30-49




250 to 750 mg twice daily




Severe




< 30




250 to 500 mg twice daily




End-stage renal disease patients undergoing dialysis (1)




-




500 to 1,000 mg once daily (2)



(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.



(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.



For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.



The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents, children and infants, using the following formula (Schwartz formula):





ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years; ks= 0.7 in adolescent male



Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function
































Group




Creatinine clearance



(ml/min/1.73m2)




Dosage frequency


 


Infants 1 to less than 6 months




Infants 6 to 23 months, children and adolescents weighing less than 50 kg


  


Normal




> 80




7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily




10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily




Mild




50-79




7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily




10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily




Moderate




30-49




3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily




5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily




Severe




< 30




3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily




5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily




End-stage renal disease patients undergoing dialysis



 


7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily (1) (3)




10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily (2) (4)



(1) A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.



(2) A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.



(3) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.



(4) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.



Hepatic impairment



No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2.



Paediatric population



The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight and dose.



Monotherapy



The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.



There are no data available.



Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg



The initial therapeutic dose is 10 mg/kg twice daily.



Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.



Dosage in children 50 kg or greater is the same as in adults.



Dosage recommendations for infants from 6 months of age, children and adolescents:

























Weight




Starting dose:



10 mg/kg twice daily




Maximum dose:



30 mg/kg twice daily




6 kg (1)




60 mg (0.6 mL) twice daily




180 mg (1.8 mL) twice daily




10 kg (1)




100 mg (1 mL) twice daily




300 mg (3 mL) twice daily




15 kg (1)




150 mg (1.5 mL) twice daily




450 mg (4.5 mL) twice daily




20 kg (1)




200 mg (2 mL) twice daily




600 mg (6 mL) twice daily




25 kg




250 mg twice daily




750 mg twice daily




From 50 kg (2)




500 mg twice daily




1,500 mg twice daily



(1) Children 20 kg or less should preferably start the treatment with levetiracetam 100 mg/ml oral solution.



(2) Dosage in children and adolescents 50 kg or more is the same as in adults.



Add-on therapy for infants from 1 month to less than 6 months



The initial therapeutic dose is 7 mg/kg twice daily.



Depending upon the clinical response and tolerability, the dose can be increased up to 21 mg/kg twice daily. Dose changes should not exceed increases or decreases of 7 mg/kg twice daily every two weeks.



The lowest effective dose should be used.



Infants should start the treatment with levetiracetam 100 mg/ml oral solution.



Dose recommendations for infants less than 6 months:
















Weight




Starting dose:



7 mg/kg twice daily




Maximum dose:



21 mg/kg twice daily




4 kg




28 mg (0.3 mL) twice daily




84 mg (0.85 mL) twice daily




5 kg




35 mg (0.35 mL) twice daily




105 mg (1.05 mL) twice daily




7 kg




49 mg (0.5 mL)twice daily




147 mg (1.5 mL) twice daily



The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight and dose.



Three presentations are available:



- A 300 ml bottle with graduated oral syringe containing up to 1000 mg levetiracetam (corresponding to 10 ml) with a graduation every 0.25 ml (corresponding to 25 mg).



- A 150 ml bottle with graduated oral syringe containing up to 300 mg levetiracetam (corresponding to 3 ml) with a graduation every 0.1 ml (corresponding to 10 mg).



In order to ensure the accuracy of the dosing, the smaller bottle (150 ml) and syringe graduated from 0.1 to 3 ml per graduation of 0.1 ml should be prescribed for infants older than 6 months and young children.



- A 150 ml bottle with graduated oral syringe containing up to 100 mg levetiracetam (corresponding to 1 ml) with a graduation every 0.05 ml (corresponding to 5 mg).



In order to ensure the accuracy of the dosing, the smaller bottle (150 ml) and syringe graduated from 0.05 to 1 ml per graduation of 0.05 ml should be prescribed for infants less than 6 months.



Method of administration



The oral solution may be diluted in a glass of water and may be taken with or without food. A graduated oral syringe, an adaptor for the syringe and instructions for use in the package leaflet are provided with levetiracetam. The daily dose is administered in two equally divided doses.



4.3 Contraindications



Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients.



4.4 Special Warnings And Precautions For Use



Discontinuation



In accordance with current clinical practice, if levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/ kg twice daily every two weeks).



Renal insufficiency



The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).



Suicide



Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic drugs has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.



Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.



Paediatric population



Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.



The safety and efficacy of levetiracetam has not been thoroughly assessed in infants aged less than 1 year. Only 35 infants aged less than 1 year have been exposed in clinical studies of which only 13 were aged < 6 months.



Excipients



Levetiracetam 100 mg/ml oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). It also includes maltitol liquid; patients with rare hereditary problems of fructose intolerance should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Antiepileptic medicinal products



Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.



As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.



A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dosage adjustment is not required.



Probenecid



Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted medicinal products, e.g. NSAIDs, sulfonamides and methotrexate, is unknown.



Oral contraceptives and other pharmacokinetics interactions



Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.



Antacids



No data on the influence of antacids on the absorption of levetiracetam are available.



Food and alcohol



The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.



No data on the interaction of levetiracetam with alcohol are available.



4.6 Pregnancy And Lactation



Pregnancy



There are no adequate data from the use of levetiracetam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for human is unknown. Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary.



As with other antiepileptic drugs, physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.



Breastfeeding



Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.



Fertility



No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.



4.8 Undesirable Effects



Summary of the safety profile



Pooled safety data from clinical studies conducted with levetiracetam oral formulations in adult patients with partial onset seizures showed that 46.4 % of the patients in the levetiracetam group and 42.2 % of the patients in the placebo group experienced undesirable effects. Serious undesirable effects were experienced in 2.4% of the patients in the levetiracetam and 2.0% of the patients in the placebo groups. The most commonly reported undesirable effects were somnolence, asthenia and dizziness. In the pooled safety analysis, there was no clear dose-response relationship but incidence and severity of the central nervous system related undesirable effects decreased over time.



In monotherapy 49.8 % of the subjects experienced at least one drug related undesirable effect. The most frequently reported undesirable effects were fatigue and somnolence.



A study conducted in adults and adolescents with myoclonic seizures (12 to 65 years) showed that 33.3% of the patients in the levetiracetam group and 30.0% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment. The most commonly reported undesirable effects were headache and somnolence. The incidence of undesirable effects in patients with myoclonic seizures was lower than that in adult patients with partial onset seizures (33.3% versus 46.4%).



A study conducted in adults and children (4 to 65 years) with idiopathic generalised epilepsy with primary generalised tonic-clonic seizures showed that 39.2 % of the patients in the Levetiracetam group and 29.8 % of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment. The most commonly reported undesirable effect was fatigue.



An increase in seizure frequency of more than 25 % was reported in 14 % of levetiracetam treated adult and paediatric patients (4 to 16 years of age) with partial onset seizures, whereas it was reported in 26 % and 21 % of placebo treated adult and paediatric patients, respectively.



When Levetiracetam was used to treat primary generalised tonic-clonic seizures in adults and adolescents with idiopathic generalised epilepsy, there was no effect on the frequency of absences.



Tabulated list of adverse reactions



Adverse reactions reported in clinical studies (adults, adolescents, children and infants > 1 month) or from post-marketing experience are listed in the following table per System Organ Class and per frequency. For clinical trials, the frequency is defined as follows: very common (



- Infections and infestations



Common: infection, nasopharyngitis



- Blood and lymphatic system disorders



Common: thrombocytopenia



Post-marketing experience: leukopenia, neutropenia, pancytopenia (with bone marrow suppression identified in some of the cases).



- Metabolism and nutrition disorders



Common: anorexia, weight increase.



The risk of anorexia is higher when topiramate is coadministered with levetiracetam.



Post-marketing experience: weight loss



- Psychiatric disorders



Common: agitation, depression, emotional lability/mood swings, hostility/aggression, insomnia, nervousness/irritability, personality disorders, thinking abnormal



Post-marketing experience: abnormal behaviour, anger, anxiety, confusion, hallucination, psychotic disorder, suicide, suicide attempt and suicidal ideation



- Nervous system disorders



Very common: somnolence



Common: amnesia, ataxia, convulsion, dizziness, headache, hyperkinesia, tremor, balance disorder, disturbance in attention, memory impairment.



Post-marketing experience: paraesthesia



- Eye disorders



Common: diplopia, vision blurred



- Ear and labyrinth disorders



Common: vertigo



- Respiratory, thoracic and mediastinal disorders



Common: cough increased



- Gastrointestinal disorders



Common: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting



Post-marketing experience: pancreatitis



- Hepatobiliary disorders:



Post-marketing experience: hepatic failure, hepatitis, liver function test abnormal



- Skin and subcutaneous tissue disorders



Common: rash, eczema, pruritus



Post-marketing experience: alopecia: in several cases, recovery was observed when levetiracetam was discontinued.



- Musculoskeletal and connective tissue disorders



Common: myalgia



- General disorders and administration site conditions



Very common: asthenia/fatigue.



- Injury, poisoning and procedural complications



Common: accidental injury



Description of selected adverse reactions



The risk of anorexia is higher when topiramate is coadministered with levetiracetam.



In several cases of alopecia, recovery was observed when levetiracetam was discontinued.



Paediatric population



A study conducted in paediatric patients (4 to 16 years) with partial onset seizures showed that 55.4 % of the patients in the levetiracetam group and 40.2 % of the patients in the placebo group experienced undesirable effects. Serious undesirable effects were experienced in 0.0 % of the patients in the levetiracetam group and 1.0 % of the patients in the placebo group. The most commonly reported undesirable effects were somnolence, hostility, nervousness, emotional lability, agitation, anorexia, asthenia and headache in the paediatric population. Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse events which were more common in children than in adults (38.6% versus 18.6%). However, the relative risk was similar in children as compared to adults.



A study conducted in paediatric patients (1 month to less than 4 years) with partial onset seizures showed that 21.7 % of the patients in the levetiracetam group and 7.1 % of the patients in the placebo group experienced undesirable effects. No Serious undesirable effects were experienced in patients in the levetiracetam or Placebo group. During the long-term follow-up study N01148, the most frequent drug-related treatment-emergent adverse events in the 1m - <4y group were irritability (7.9%), convulsion (7.2%), somnolence (6.6%), psychomotor hyperactivity (3.3%), sleep disorder (3.3%), and aggression (3.3%). Safety results in paediatric patients were consistent with the safety profile of levetiracetam in older children aged 4 to 16 years.



A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardized and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist). However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.



4.9 Overdose



Symptoms



Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses.



Management of overdose



After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14. The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.



Mechanism of action



The mechanism of action of levetiracetam still remains to be fully elucidated but appears to be different from the mechanisms of current antiepileptic medicinal products. In vitro and in vivo experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.



In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.



Pharmacodynamic effects



Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.



In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.



Clinical experience



Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy:



In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6% for patients on placebo.



Paediatric population



In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).



44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.



In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six month and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 month to less than 4 years old, was use in this study. The total daily dose was administered b.i.d.



The primary measure of effectiveness was the responder rate (percent of patients with



Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.



Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 - 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.



Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).



In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).



Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.



Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.



In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.



58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.



Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.



Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.



72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.



5.2 Pharmacokinetic Properties



Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.



Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore there is no need for plasma level monitoring of levetiracetam.



A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).



Adults and adolescents



Absorption



Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100 %.



Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.



Peak concentrations (Cmax) are typically 31 and 43 µg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.



The extent of absorption is dose-independent and is not altered by food.



Distribution



No tissue distribution data are available in humans.



Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10 %). The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.



Biotransformation



Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.



Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose). Other unidentified components accounted only for 0.6 % of the dose.



No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite.



In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.



In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo. Therefore, the interaction of levetiracetam with other substances, or vice versa, is unlikely.



Elimination



The plasma half-life in adults was 7±1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.



The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion via faeces accounted for only 0.3 % of the dose.



The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.



The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration.



Levetiracetam elimination is correlated to creatinine clearance.



Elderly



In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).



Renal impairment



The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).



In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.



The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.



Hepatic impairment



In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).



Peadiatric population



Children (4 to 12 years)



Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.



Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.



Infants and children (1 month to 4 years)



Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epilepti

Cloderm


Generic Name: clocortolone topical (kloe KOR toe lone)

Brand Names: Cloderm


What is Cloderm (clocortolone topical)?

Clocortolone is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.


Clocortolone topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.


Clocortolone topical may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Cloderm (clocortolone topical)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with clocortolone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period. Contact your doctor if your condition does not improve, or if you develop signs of a bacterial, fungal, or viral skin infection.

What should I discuss with my healthcare provider before using Cloderm (clocortolone topical)?


Do not use this medication if you are allergic to clocortolone.

Before using clocortolone topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.


Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.


FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether clocortolone topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period.

How should I use Cloderm (clocortolone topical)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.


Wash your hands before and after using clocortolone topical, unless you are using the medication to treat the skin on your hands.

Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with clocortolone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Contact your doctor if your condition does not improve, or if you develop signs of a bacterial, fungal, or viral skin infection. It is important to use clocortolone topical regularly to get the most benefit.

To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.


Store clocortolone topical at room temperature away from moisture and heat. Keep from freezing.

What happens if I miss a dose?


Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of clocortolone is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.


What should I avoid while using Cloderm (clocortolone topical)?


Clocortolone topical should not be used to treat any skin condition your doctor has not prescribed it for.


Avoid getting this medication in your eyes. If contact does occur, rinse with water. Do not use clocortolone topical on broken or infected skin. Also avoid using this medication in open wounds.

Cloderm (clocortolone topical) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have severe irritation of any treated skin, or if you show signs of absorbing clocortolone topical through your skin, such as:

  • blurred vision, or seeing halos around lights;




  • mood changes;




  • sleep problems (insomnia);




  • weight gain, puffiness in your face; or




  • muscle weakness, feeling tired.



Less serious side effects may include:



  • mild skin itching, burning, peeling, or dryness;




  • thinning or softening of your skin;




  • skin rash or irritation around your mouth;




  • swollen hair follicles;




  • changes in color of treated skin;




  • blisters, pimples, or crusting of treated skin; or




  • stretch marks.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Cloderm (clocortolone topical)?


It is not likely that other drugs you take orally or inject will have an effect on topically applied clocortolone topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Cloderm resources


  • Cloderm Side Effects (in more detail)
  • Cloderm Use in Pregnancy & Breastfeeding
  • Cloderm Drug Interactions
  • Cloderm Support Group
  • 3 Reviews for Cloderm - Add your own review/rating


  • Cloderm Prescribing Information (FDA)

  • Cloderm MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Cloderm with other medications


  • Atopic Dermatitis
  • Dermatitis
  • Eczema
  • Psoriasis


Where can I get more information?


  • Your pharmacist can provide more information about clocortolone topical.

See also: Cloderm side effects (in more detail)


Tuesday, 7 August 2012

Zavesca (miglustat) 100 mg hard capsules






Zavesca 100 mg hard capsules


Miglustat



Read all of this leaflet carefully before you start taking this medicine.


  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, please ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



In this leaflet:


1. What Zavesca is and what it is used for

2. Before you take Zavesca

3. How to take Zavesca

4. Possible side effects

5. How to store Zavesca

6. Further information





What Zavesca Is And What It Is Used For


Zavesca belongs to a group of medicines that affect metabolism. It is used to treat two conditions:



  • Zavesca is used to treat mild to moderate type 1 Gaucher disease.

In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. It starts to build up in certain cells of the body’s immune system. This can result in liver and spleen enlargement, changes in the blood, and bone disease.


The usual treatment for type 1 Gaucher disease is enzyme replacement therapy. Zavesca is only used when a patient is considered unsuitable for treatment with enzyme replacement therapy.



  • Zavesca is also used to treat progressive neurological symptoms in Niemann-Pick type C disease.

If you have Niemann-Pick type C disease, fats such as glycosphingolipids build up in the cells of your brain. This can result in disturbances in neurological functions such as eye movements, balance, swallowing, and memory, and in seizures.


Zavesca works by inhibiting the enzyme called ‘glucosylceramide synthase’ which is responsible for the first step in the synthesis of most glycosphingolipids.




Before You Take Zavesca



Do not take Zavesca


  • if you are allergic (hypersensitive) to miglustat or any of the other ingredients of Zavesca. If this applies to you, tell your doctor. Don’t take Zavesca.



Take special care with Zavesca


  • if you suffer from kidney disease

  • if you suffer from liver disease

If any of these apply to you, tell your doctor before you take Zavesca.


Your doctor will perform the following tests before treatment and during treatment with Zavesca:


  • an examination to check the nerves in your arms and legs

  • measurement of vitamin B12 levels

  • monitoring growth if you are a child or adolescent with Niemann-Pick type C disease

  • monitoring of blood platelet counts if you are a patient with Niemann-Pick type C disease

The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or a decrease in body weight, while taking Zavesca. The tests will help the doctor decide whether these effects are due to your disease or other existing conditions, or due to side effects of Zavesca (see section 4 for further details).


If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and carbohydrate intake, or not to take Zavesca together with food, or to temporarily reduce your dose. In some cases the doctor may prescribe anti-diarrhoeal medicines such as loperamide. If your diarrhoea does not respond to these measures, or if you have any other abdominal complaint, consult your doctor. In such case, your doctor may decide to conduct further investigations.


Male patients should use reliable birth control methods during their treatment with Zavesca, and for 3 months after finishing treatment.




Using other medicines


Talk to your doctor if you are using Cerezyme, or other medicines containing imiglucerase, which are sometimes used at the same time as Zavesca. They may lower the amount of Zavesca in your body. Please tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without prescription.




Taking Zavesca with food and drink


Zavesca can be taken with or without food. You should swallow the whole capsule with a glass of water.




Pregnancy and breast-feeding


You should not use Zavesca if you are pregnant or thinking of becoming pregnant. Your doctor can give you more information. You must use effective birth control while using Zavesca. Do not breast-feed while you are using Zavesca.


Male patients should use reliable birth control methods during their treatment with Zavesca, and for 3 months after finishing treatment.


Ask your doctor or pharmacist for advice before taking any medicine.




Driving and using machines


Zavesca may make you feel dizzy. Do not drive or use any tools or machines if you feel dizzy.





How To Take Zavesca


Always take Zavesca exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure about any of the instructions.



  • For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a day (morning, afternoon and evening). This means a daily maximum of three capsules (300 mg).


  • For Niemann-Pick type C disease: For adults and adolescents, the usual dose is two capsules (200 mg) three times a day (morning, afternoon and evening). This means a daily maximum of six capsules (600 mg).

If you are less than 12 years old, your doctor will adjust your dose for Niemann-Pick type C disease.


If you have a problem with your kidneys you may receive a lower starting dose. Your doctor may reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when taking Zavesca (see section 4). Your doctor will tell you how long your treatment will last.



To remove the capsule:



1. Separate at perforations

2. Peel back paper at arrows

3. Push product through foil


The Zavesca capsule should be swallowed whole with water.




If you take more Zavesca than you should


If you take more capsules than you were told to, consult your doctor immediately. Zavesca has been used in clinical trials at doses ten times higher than the recommended dose: this caused decreases in white blood cells and other side effects similar to those described in section 4.




If you forget to take Zavesca


Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose.




If you stop taking Zavesca


Don't stop Zavesca without talking to your doctor.



If you have any further questions on the use of this medicine, ask your doctor or pharmacist.




Possible Side Effects


Like all medicines, Zavesca can cause side effects, although not everybody gets them.



Very common effects - likely to affect more than 1 in 10 people


The most common side effects are weight loss, tremor, diarrhoea, flatulence (wind), abdominal (stomach) pain.



Common effects - likely to affect less than 1 in 10 people and more than 1 in 100 people


Common side effects of treatment include anorexia (lack of appetite), decreased appetite, headache, dizziness, peripheral neuropathy, paraesthesia (tingling or numbness), abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea (feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and thrombocytopenia (reduced levels of blood platelets). The neurological symptoms and thrombocytopenia could be due to the underlying disease.


Other possible side effects are muscular spasms or weakness, fatigue, difficulty sleeping, and less libido.


Most patients get one or more of these side effects, usually at the start of treatment or at intervals during treatment. Most cases are mild and disappear quite quickly. If any of these side effects cause problems, consult your doctor. He or she may reduce the dose of Zavesca or recommend other medicines to help control side effects.



Some patients have had tingling or numbness in the hands and feet. They could be signs of peripheral neuropathy, due to side effects of Zavesca or they could be due to existing conditions. Your doctor will perform some tests before and during treatment with Zavesca to assess this (see section 2).



If you do get any of these effects, please report them to your doctor as soon as possible.



If you do lose some weight when you start treatment with Zavesca don't worry. People usually stop losing weight as treatment goes on.



If you get a slight tremor, usually trembling hands, report it to your doctor as soon as possible. The tremor often disappears without needing to stop the treatment. Sometimes your doctor will need to reduce the dose or stop Zavesca treatment to stop the tremor.



If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



For storage and other information, please turn over.




How To Store Zavesca


Keep out of the reach and sight of children.


Do not use Zavesca after the expiry date stated on the carton.


Store below 30 °C.



Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.




Further Information



What Zavesca contains



The active substance is miglustat 100 mg.



Other ingredients in the capsule are:


Sodium starch glycollate,


Povidone (K30),


Magnesium stearate.



Other ingredients in the capsule shell are:


Gelatin,


Water,


Titanium dioxide (E171).



Other ingredients in the Printing ink are:


Black iron oxide (E172)


Shellac.




What Zavesca looks like and contents of the pack


Zavesca is a white 100 mg capsule with “OGT 918” printed in black on the cap and “100” printed in black on the body.


Box of 4 blister strips, each blister strip containing 21 capsules providing a total of 84 capsules.




Marketing Authorisation Holder:



Actelion Registration Ltd

BSI Building 13th Floor

389 Chiswick High Road

London

W4 4AL

United Kingdom




Manufacturer responsible for batch release:



Actelion Pharmaceuticals Deutschland GmbH

Basler strasse 63-65

79100 Freiburg

Germany



For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.




United Kingdom

Actelion Pharmaceuticals UK Ltd

Tel:+44-(0)845 075 0555




This leaflet was last approved in: June 2010


This medicine has been authorised under "Exceptional Circumstances". This means that because of the rarity of this disease it has been impossible to get complete information on this medicine. The European Medicines Agency (EMA) will review any new information on the medicine every year and this leaflet will be updated as necessary.


Detailed information on this medicine is available on the European Medicines Agency (EMA) website: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.





Saturday, 28 July 2012

chlorophyllin


Generic Name: chlorophyllin (KLOR oh fil in)

Brand names: Derifil, Chloresium, Derifil(obsolete), PALS


What is chlorophyllin?

Chlorophyllin is used as an internal deodorant. It has been used to improve breath odor as well as odors from urine, bowel movements (feces), or wound infections.


Chlorophyllin is used to reduce the odor of bowel movements (feces). It works by preventing bacteria in the intestines from forming odor-producing substances in stools.


Chlorophyllin is intended to improve the quality of life in people who have fecal incontinence due to spinal cord injury, bowel cancer, psychotic disorder, terminal illness, or other disorders. Chlorophyllin is also used by people who have had a colostomy or ileostomy.


Chlorophyllin has also been used in alternative medicine as an antioxidant or anti-inflammatory aid.


Not all uses for chlorophyllin have been approved by the FDA. Chlorophyllin should not be substituted for prescription medications.

Chlorophyllin is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Chlorophyllin may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about chlorophyllin?


Not all uses for chlorophyllin have been approved by the FDA. Chlorophyllin should not be substituted for prescription medications.

Use this medication as directed on the label, or as your doctor has prescribed. Do not use the medication in larger amounts or for longer than recommended.


Tell your doctor about all other medications you use, especially insulin or diabetes medications you take by mouth, cholesterol-lowering medicines, or drugs that weaken your immune system (such as cancer medicine or steroids).


Get emergency medical help if you think you have used too much medicine, or if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using chlorophyllin and call your doctor if you have severe stomach cramps or diarrhea. Chlorophyllin may cause loose stools, but this should be a temporary effect.

Your urine or stools may appear green in color. This is a normal side effect of chlorophyllin and is not cause for concern.


Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Chlorophyllin can make your skin more sensitive to sunlight and sunburn skin may result. Use a sunscreen (minimum SPF 15) and wear protective clothing if you must be out in the sun.

What should I discuss with my health care provider before taking chlorophyllin?


Before using chlorophyllin, tell your doctor if you are allergic to any drugs, or if you have:



  • liver disease;




  • diabetes;




  • cancer; or




  • a weak immune system.



If you have any of these conditions, you may not be able to take chlorophyllin, or you may need a dose adjustment or special tests during treatment.


FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Chlorophyllin may pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take chlorophyllin?


Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.


Your doctor may occasionally change your dose to make sure you get the best results from this medication.


It may take several days of using this medicine before fecal odor is completely controlled.. For best results, keep using the medication as directed. Store chlorophyllin at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include severe stomach pain or diarrhea.


What should I avoid while taking chlorophyllin?


Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Chlorophyllin can make your skin more sensitive to sunlight and sunburn skin may result. Use a sunscreen (minimum SPF 15) and wear protective clothing if you must be out in the sun.

Chlorophyllin side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using chlorophyllin and call your doctor if you have severe stomach cramps or diarrhea. Chlorophyllin may cause loose stools, but this should be a temporary effect.

Your urine or stools may appear green in color. This is a normal side effect of chlorophyllin and is not cause for concern.


This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect chlorophyllin?


Tell your doctor about all other medications you use, especially:



  • insulin or diabetes medications you take by mouth;




  • cholesterol-lowering medicines such as atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), pravastatin (Pravachol), fluvastatin (Lescol), or cerivastatin (Baycol); or




  • drugs that weaken your immune system (such as cancer medicine or steroids).



This list is not complete and there may be other drugs that can interact with chlorophyllin. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More chlorophyllin resources


  • Chlorophyllin Support Group
  • 0 Reviews · Be the first to review/rate this drug


Where can I get more information?


  • Your pharmacist can provide more information about chlorophyllin.


Friday, 27 July 2012

GenTeal


Generic Name: ocular lubricant (OK yoo lar LOO bri kant)

Brand Names: Artificial Tears, Celluvisc, Clear Eyes CLR, Comfort Tears, Dry Eye Relief, GenTeal, Isopto Tears, Lacri-Lube S.O.P., Lacrisert, Lubricant Eye Drops, Moisture Drops, Oasis Tears, Opti-Free Rewetting Drops, optive, Refresh, Soothe, Sterilube, Systane, Systane Balance, Tears Again, Tears Naturale, Tears Renew, TheraTears, Ultra Fresh, Visine Tears


What is GenTeal (ocular lubricant)?

There are many brands and forms of ocular lubricant available and not all are listed on this leaflet.


Ocular lubricant is a solution specially formulated to moisten the eyes.


Ocular lubricant is used to relieve burning, irritation, and discomfort caused by dry eyes.

Ocular lubricant may also be used for purposes not listed in this medication guide.


What is the most important information I should know about GenTeal (ocular lubricant)?


There are many brands and forms of ocular lubricant available and not all are listed on this leaflet.


You should not use an ocular lubricant if you are allergic to it. Ocular lubricant will not treat or prevent an eye infection.

Ask a doctor or pharmacist if it is safe for you to use this medicine if you have any type of infection in your eye.


Do not allow the dropper or tube tip to touch any surface, including the eyes or hands. If the dropper or tube becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.


Stop using ocular lubricant and call your doctor if you have severe burning, stinging, irritation, eye pain, or vision changes.

This medication may cause blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.


Talk with your doctor if your symptoms do not improve or if they get worse while you are using ocular lubricant.

What should I discuss with my healthcare provider before using GenTeal (ocular lubricant)?


You should not use an ocular lubricant if you are allergic to it. Ocular lubricant will not treat or prevent an eye infection.

Ask a doctor or pharmacist if it is safe for you to use this medicine if you have any type of infection in your eye.


Ocular lubricant is not expected to harm an unborn baby. Ask a doctor or pharmacist about using ocular lubricant if you are pregnant. It is not known whether ocular lubricant passes into breast milk or if it could harm a nursing baby. Ask a doctor or pharmacist about using ocular lubricant if you are pregnant.

How should I use GenTeal (ocular lubricant)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.


Do not use this medication while wearing contact lenses. Eye medication may contain a preservative that can discolor soft contact lenses. Wait at least 15 minutes after using this medication before putting your contact lenses in. Wash your hands before using ocular lubricant.

To apply the eye drops:



  • Tilt your head back slightly and pull down your lower eyelid to create a small pocket. Hold the dropper above the eye with the tip down. Look up and away from the dropper as you squeeze out a drop, then close your eye.




  • Use only the number of drops your doctor has prescribed.




  • Gently press your finger to the inside corner of the eye (near your nose) for about 1 minute to keep the liquid from draining into your tear duct. If you use more than one drop in the same eye, wait about 5 minutes before putting in the next drop.




  • Do not use the eye drops if the liquid has changed colors or has particles in it.



To apply the ointment:



  • Tilt your head back slightly and pull down your lower eyelid to create a small pocket. Hold the ointment tube with the tip pointing toward this pocket. Look up and away from the tip.




  • Squeeze out a ribbon of ointment 1/2-inch long into the lower eyelid pocket without touching the tip of the tube to your eye. Look down and close your eyes for a few minutes. Rolling your eyes around gently will help spread the ointment evenly.




  • After opening your eyes, you may have blurred vision for a short time. Avoid driving or doing anything that requires you to be able to see clearly.



Do not allow the dropper or tube tip to touch any surface, including the eyes or hands. If the dropper or tube becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.


Talk with your doctor if your symptoms do not improve or if they get worse while you are using ocular lubricant. Store at room temperature away from moisture and heat. Do not freeze. Keep the bottle or tube tightly closed when not in use.

What happens if I miss a dose?


Since ocular lubricant is used on an as needed basis, you are not likely to miss a dose.


What happens if I overdose?


An overdose of ocular lubricant is not expected to be dangerous.


What should I avoid while using GenTeal (ocular lubricant)?


This medication may cause blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.


Avoid using other medications in your eyes during treatment with ocular lubricant unless your doctor tells you to.


GenTeal (ocular lubricant) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using ocular lubricant and call your doctor if you have a serious side effect such as:

  • severe burning, stinging, or eye irritation after using the medication;




  • eye pain; or




  • vision changes.



Less serious side effects may include:



  • mild eye burning or irritation;




  • itching or redness of your eyes;




  • watery eyes;




  • blurred vision; or




  • unpleasant taste in your mouth.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect GenTeal (ocular lubricant)?


It is not likely that other drugs you take orally or inject will have an effect on ocular lubricant used in the eyes. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More GenTeal resources


  • GenTeal Use in Pregnancy & Breastfeeding
  • GenTeal Support Group
  • 0 Reviews for GenTeal - Add your own review/rating


  • FreshKote Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Genteal Advanced Consumer (Micromedex) - Includes Dosage Information

  • Lacri-Lube S.O.P. Ointment MedFacts Consumer Leaflet (Wolters Kluwer)

  • Lacrisert Prescribing Information (FDA)

  • Lacrisert Insert MedFacts Consumer Leaflet (Wolters Kluwer)

  • Lacrisert Advanced Consumer (Micromedex) - Includes Dosage Information

  • Murine Tears Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Murocel Eye Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Refresh Redness Relief Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Refresh liquigel



Compare GenTeal with other medications


  • Eye Dryness/Redness


Where can I get more information?


  • Your pharmacist can provide more information about ocular lubricant.


Thursday, 26 July 2012

Zinc Sulfate


Pronunciation: zink SUL-fate
Generic Name: Zinc Sulfate
Brand Name: Examples include Orazinc and Zincate


Zinc Sulfate is used for:

Treating zinc deficiency. It may also be used for other conditions as determined by your doctor.


Zinc Sulfate is a mineral. It works by replacing zinc in the body.


Do NOT use Zinc Sulfate if:


  • you are allergic to any ingredient in Zinc Sulfate

Contact your doctor or health care provider right away if any of these apply to you.



Before using Zinc Sulfate:


Some medical conditions may interact with Zinc Sulfate. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances (including dairy products)

  • if you have low levels of copper in the blood

Some MEDICINES MAY INTERACT with Zinc Sulfate.


Ask your health care provider if Zinc Sulfate may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Zinc Sulfate:


Use Zinc Sulfate as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Zinc Sulfate by mouth with a meal.

  • Avoid taking Zinc Sulfate at the same time as foods that contain bran, calcium, or phosphorus. They may decrease the amount of Zinc Sulfate absorbed into the body.

  • If you take eltrombopag, a quinolone antibiotic (eg, levofloxacin), or a tetracycline antibiotic (eg, doxycycline), ask your doctor or pharmacist how to take it with Zinc Sulfate.

  • If you miss a dose of Zinc Sulfate, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Zinc Sulfate.



Important safety information:


  • Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • Zinc Sulfate should not be used in CHILDREN younger than 12 years old without first checking with the child's doctor; safety and effectiveness in these children has not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Zinc Sulfate while you are pregnant. Zinc Sulfate is found in breast milk. If you are or will be breast-feeding while you use Zinc Sulfate, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Zinc Sulfate:


All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Nausea; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); severe vomiting; unusual restlessness; very dry mouth, eyes, or skin.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include severe vomiting; unusual restlessness; unusual tiredness or weakness; or very dry mouth, eyes, or skin.


Proper storage of Zinc Sulfate:

Store Zinc Sulfate at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Zinc Sulfate out of the reach of children and away from pets.


General information:


  • If you have any questions about Zinc Sulfate, please talk with your doctor, pharmacist, or other health care provider.

  • Zinc Sulfate is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Zinc Sulfate. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Zinc Sulfate resources


  • Zinc Sulfate Use in Pregnancy & Breastfeeding
  • Drug Images
  • Zinc Sulfate Drug Interactions
  • Zinc Sulfate Support Group
  • 1 Review for Zinc Sulfate - Add your own review/rating


  • Zinc Sulfate Professional Patient Advice (Wolters Kluwer)

  • zinc sulfate Concise Consumer Information (Cerner Multum)

  • Orazinc 110 Concise Consumer Information (Cerner Multum)

  • Orazinc 110 Advanced Consumer (Micromedex) - Includes Dosage Information

  • Zinc 50 mg Pink Concise Consumer Information (Cerner Multum)



Compare Zinc Sulfate with other medications


  • Vitamin/Mineral Supplementation and Deficiency